Switch to Rosuvastatin Plus Ezetimibe From Statin Monotherapy to Achieve Target LDL-Cholesterol Goal: A Multi-Center, Open-Label, Single-Arm Trial.
作者信息
Park Hong-Kyun, Park Jong-Ho, Park Hee-Kwon, Kang Kyusik, Jung Keun-Hwa, Kim Beom Joon, Jung Jin-Man, Kim Young Seo, Lee Yong-Seok, Nam Hyo Suk, Yu Yeonju, Lee Juneyoung, Hong Keun-Sik
机构信息
Department of Neurology, Inje University Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
出版信息
J Stroke. 2025 May;27(2):275-278. doi: 10.5853/jos.2024.05015. Epub 2025 May 31.
Abstract
摘要
相似文献
1
Switch to Rosuvastatin Plus Ezetimibe From Statin Monotherapy to Achieve Target LDL-Cholesterol Goal: A Multi-Center, Open-Label, Single-Arm Trial.从他汀类单药治疗转换为瑞舒伐他汀联合依折麦布以实现低密度脂蛋白胆固醇目标：一项多中心、开放标签、单臂试验。
J Stroke. 2025 May;27(2):275-278. doi: 10.5853/jos.2024.05015. Epub 2025 May 31.
2
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.与他汀类单药治疗滴定相比，依折麦布联合辛伐他汀、阿托伐他汀或瑞舒伐他汀治疗时低密度脂蛋白胆固醇（LDL-C）水平的变化及目标达成情况。
Vasc Health Risk Manag. 2013;9:719-27. doi: 10.2147/VHRM.S49840. Epub 2013 Nov 15.
3
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.与将他汀类药物剂量加倍相比，依折麦布联合他汀类药物附加治疗或转换治疗实现目标血脂水平的一项汇总分析。
Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.
4
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.瑞西伐他汀与依折麦布联合中等强度他汀治疗与高强度他汀单药治疗动脉粥样硬化性心血管疾病患者的长期疗效和安全性（RACING）：一项随机、开放标签、非劣效性试验。
Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18.
5
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.匹伐他汀联合依折麦布治疗急性冠状动脉综合征合并血脂异常患者的低密度脂蛋白胆固醇靶向治疗：HIJ-PROPER研究，一项前瞻性、开放标签、随机试验
Eur Heart J. 2017 Aug 1;38(29):2264-2276. doi: 10.1093/eurheartj/ehx162.
6
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).瑞舒伐他汀40毫克单药治疗或与依折麦布联合治疗心血管疾病高危患者的疗效与安全性（EXPLORER研究结果）
Am J Cardiol. 2007 Mar 1;99(5):673-80. doi: 10.1016/j.amjcard.2006.10.022. Epub 2007 Jan 4.
7
Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial.中等强度瑞舒伐他汀联合依折麦布与高强度瑞舒伐他汀在近期缺血性卒中患者中实现低密度脂蛋白胆固醇目标值的比较：一项随机对照试验
J Stroke. 2023 May;25(2):242-250. doi: 10.5853/jos.2022.02957. Epub 2023 Apr 11.
8
Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial.瑞舒伐他汀与依折麦布固定剂量复方制剂与辛伐他汀与依折麦布固定剂量复方制剂治疗巴西原发性高胆固醇血症或混合性血脂异常患者的疗效和耐受性：一项多中心随机试验
Curr Ther Res Clin Exp. 2020 Jul 28;93:100595. doi: 10.1016/j.curtheres.2020.100595. eCollection 2020.
9
Effect of rosuvastatin 20 mg versus rosuvastatin 5 mg plus ezetimibe on statin side-effects in elderly patients with atherosclerotic cardiovascular disease: Rationale and design of a randomized, controlled SaveSAMS trial.瑞舒伐他汀 20 毫克与瑞舒伐他汀 5 毫克加依折麦布对老年动脉粥样硬化性心血管疾病患者他汀类药物副作用的影响：随机、对照 SaveSAMS 试验的原理和设计。
Am Heart J. 2023 Jul;261:45-50. doi: 10.1016/j.ahj.2023.03.002. Epub 2023 Mar 17.
10
Efficacy, safety and effect on biomarkers related to cholesterol and lipoprotein metabolism of rosuvastatin 10 or 20 mg plus ezetimibe 10 mg vs. simvastatin 40 or 80 mg plus ezetimibe 10 mg in high-risk patients: Results of the GRAVITY randomized study.在高危患者中，瑞舒伐他汀 10 或 20mg 加依折麦布 10mg 与辛伐他汀 40 或 80mg 加依折麦布 10mg 的疗效、安全性及对胆固醇和脂蛋白代谢相关生物标志物的影响：GRAVITY 随机研究结果。
Atherosclerosis. 2014 Jan;232(1):86-93. doi: 10.1016/j.atherosclerosis.2013.10.022. Epub 2013 Nov 1.
本文引用的文献
1
Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial.中等强度瑞舒伐他汀联合依折麦布与高强度瑞舒伐他汀在近期缺血性卒中患者中实现低密度脂蛋白胆固醇目标值的比较：一项随机对照试验
J Stroke. 2023 May;25(2):242-250. doi: 10.5853/jos.2022.02957. Epub 2023 Apr 11.
2
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.瑞西伐他汀与依折麦布联合中等强度他汀治疗与高强度他汀单药治疗动脉粥样硬化性心血管疾病患者的长期疗效和安全性（RACING）：一项随机、开放标签、非劣效性试验。
Lancet. 2022 Jul 30;400(10349):380-390. doi: 10.1016/S0140-6736(22)00916-3. Epub 2022 Jul 18.
3
Achieved low-density lipoprotein cholesterol level and stroke risk: A meta-analysis of 23 randomised trials.达到的低密度脂蛋白胆固醇水平与中风风险：23项随机试验的荟萃分析
Eur J Prev Cardiol. 2021 Jul 23;28(8):905-916. doi: 10.1177/2047487319830503.
4
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.2018 年美国心脏病学会/美国心脏协会/美国心血管血管造影和介入学会/美国预防、物理治疗和康复医师学会/美国糖尿病协会/美国老年学会/美国药学会/美国医师协会/美国生理学会/北美介入放射学会/美国国家脂质协会/美国临床内分泌医师协会胆固醇管理指南：美国心脏病学会/美国心脏协会临床实践指南工作组的报告。
Circulation. 2019 Jun 18;139(25):e1082-e1143. doi: 10.1161/CIR.0000000000000625. Epub 2018 Nov 10.
5
Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.与将他汀类药物剂量加倍相比，依折麦布联合他汀类药物附加治疗或转换治疗实现目标血脂水平的一项汇总分析。
Atherosclerosis. 2014 Dec;237(2):829-37. doi: 10.1016/j.atherosclerosis.2014.10.105. Epub 2014 Nov 4.
6
Lipid-lowering treatment in hypercholesterolaemic patients: the CEPHEUS Pan-Asian survey.高胆固醇血症患者的降脂治疗：CEPHEUS 泛亚调查。
Eur J Prev Cardiol. 2012 Aug;19(4):781-94. doi: 10.1177/1741826710397100. Epub 2011 Mar 7.
7
Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.在欧洲和加拿大的临床实践中，他汀类药物治疗患者的持续性脂质异常及 LDL-胆固醇目标达标率的预测因子。
Eur J Prev Cardiol. 2012 Apr;19(2):221-30. doi: 10.1177/1741826711400545. Epub 2011 Mar 10.
8
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention.预防中风中的血脂管理：他汀类药物预防中风的综述与最新荟萃分析
Lancet Neurol. 2009 May;8(5):453-63. doi: 10.1016/S1474-4422(09)70058-4.
Zotero 插件